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Clinical sequencingHypertrophic cardiomyopathy (HCM) is caused by an autoso-
mal dominant mutation in genes that encode sarcomere proteins.
The accumulated evidence indicates that mutations in 8 sarcomere
protein genes deﬁnitively cause HCM: cardiac b-myosin heavy
chain (MYH7), cardiac myosin binding protein-C (MYBPC3),
ventricular regulatory myosin light chain (MYL2), ventricular
essential myosin light chain (MYL3), cardiac troponin T (TNNT2),
cardiac troponin I (TNNI3), a-tropomyosin (TPM1), and cardiac
actin (ACTC). These sarcomere protein genes have stood the test of
time and now underpin genetic tests for HCM. Truncating
mutation of titin gene (TTN), which is responsible for 20% of
DCM cases, is rarely identiﬁed in HCM patients [1]. The present
guidelines [2,3] recommend genetic testing for HCM patients. When
a deﬁnite pathogenic mutation is identiﬁed in an index patient, the
genetic status of each family member can be readily ascertained,
which facilitates the identiﬁcation of family members at risk for
developing HCM (i.e. cascade genetic screening). Sarcomere protein
gene mutations are known to have a strong class effect on clinical
presentation, cardiac left ventricular morphology, and survival
[4]. At present, however, due to the lack of robust data on speciﬁc
genotype-phenotype correlation, the impact of genetic testing on
clinical management is limited. From a clinician’s viewpoint,
identifying the cause of the disease would be highly appreciated,
even if it does not necessarily contribute directly to the management
of the disease at present. Currently, at least 8 sarcomere protein
genes should be sequenced in HCM patients.
In this issue of the Journal of Cardiology, Nomura et al. [5]
performed whole exome sequencing (WES) in a large HCM family
to successfully identify the previously reported Arg94His variant in
MYL3 [6,7] as a deﬁnite HCM-causing mutation. HCM-causing
mutations in MYL3 are very few in contrast with those in MYH7 and
MYBPC3. In the systemic screening of mutations in these
8 sarcomere protein genes in 112 unrelated Japanese patientsDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2015.09.003
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found in 19.6%, 10.7%, and 8.9% of cases, respectively, while
analysis of MYL2, MYL3, and ACTC did not reveal any mutations
[8]. It can be said that a comparably rare HCM-causing mutation
was successfully identiﬁed using WES in this study [5]. In
hindsight, however, the same result could have been obtained
even using the traditional Sanger sequencing of 8 sarcomere
protein genes. Given that, the success story that WES worked
remarkably well as a powerful tool for detecting the HCM-causing
mutation, rather than the identiﬁed mutation by itself, seems
noteworthy. This study clearly showed that the WES combined
with integrated variant annotation prediction could contribute to
the identiﬁcation of HCM-causing mutations. This proof-of-concept
study can be considered as a milestone toward the realization of
clinical sequencing for HCM patients. However, before the clinical
sequencing is routinely performed, a signiﬁcant number of issues
as described below must be resolved.
First, we should establish and standardize the data-processing
(annotation/ﬁltering) methods for interpreting the pathogenic
status of each sequence variant in the massive amount of WES data
so that we can efﬁciently and reliably identify the HCM-causing
mutation [9,10]. Determining whether the identiﬁed sequence
variant is a pathogenic disease-causing change or a benign variant
of no clinical signiﬁcance is a key step in the genetic testing
process, which remains a major challenge. At present, a variant is
considered to be causative of HCM based on the following criteria:
(i) a missense variant with an amino acid change at a highly
conserved position among species, (ii) a variant altering protein
structure and function (e.g. insertions/deletions causing a reading
frameshift, nonsense variants, and splice-site variants), (iii)
previously reported as an HCM-causing mutation, (iv) co-
segregation with disease in the HCM family, and (v) absence of
the variant or in <1% among unrelated and ethnically matched
controls [11]. Most importantly, even when interpreting the WES
data, segregation analysis remains the gold standard for the
acquisition of robust evidence for pathogenicity/causality [12].
Actually, in this study [5], genotype–phenotype matching (co-
segregation pattern) enabled the number of putative variants to be
narrowed down from 3439 to only 13. In order to efﬁciently and
correctly deﬁne the causative mutation, the sequencing of DNA
from relatives as well as the index patient is thought to be
essential. Also, the prediction of in silico pathogenicity for variants
using the Combined Annotation-Dependent Depletion (CADD)
prediction software [13] as well as the high heart expression gene reserved.
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this study [5]. Further improvement in prediction tools and
relevant databases should contribute to the more successful
identiﬁcation of the causative mutation.
Along with them, in order to identify the causative mutation
efﬁciently and reliably, detailed information on the frequency of
variants both in healthy control subjects and HCM patients is
essential. Next-generation, high-throughput sequencing methods
are providing extensive catalogs of human variation in the general
population (i.e. healthy control subjects). The extent of rare (<1%)
variation with an amino acid change in individual genomes turned
out to be massively greater than anticipated. Of note, a low allele
frequency is a necessary but in no way sufﬁcient criterion for a
plausible disease-causing mutation; that said, the rarity of a
variant does not necessarily mean it is pathogenic. Recently, many
variants previously described as novel and disease-causing have
been found to be present in these extensive catalogs, implying that
some of them might actually be benign rare variants of no clinical
signiﬁcance. In the Exome Sequencing Project, the prevalence of
previously reported HCM-associated variants was shown to be
more than 100 times higher than expected from the phenotype
prevalence in the general population (1:4 versus 1:500) [15]. Con-
sidering these ﬁndings, whether the identiﬁed sequence variant
was previously reported as an HCM-causing mutation or not
should not be emphasized in the annotation/ﬁltering following
WES. Now, construction of an updated extensive catalog of truly
HCM-causing mutations is essential for the realization of clinical
sequencing for HCM patients. We should perform the large-scale
WES research project with the standardized annotation/ﬁltering
methods in HCM patients registered nationwide, and establish a
robust database of the overall picture of HCM-causing mutations.
Importantly, periodic reassessment of these mutation data based
on newly available genomic information is needed [11].
Next, we must strive to understand clearly the genotype–
phenotype correlation so that we can predict the prognosis (e.g.
sudden cardiac death risk) and the response to therapy using the
genetic information. In this regard, a nationwide prospective
database of the genotype–phenotype correlation in HCM patients
should be established.
Finally, before the routine use of clinical sequencing, its clinical
usefulness should be also veriﬁed. For example, it should be
explored whether clinical sequencing could provide us with
additional information that is useful for diagnosis/management
beyond the present diagnostic methods (e.g. echocardiography,
cardiac magnetic resonance imaging). In addition, ethical, legal,
and social issues as well as proﬁt-cost balances should be assessed.
It will take years of effort to solve these many issues in genetic
research before clinical sequencing is routinely performed.
Where should we go from here? In HCM patients and their
extended family members, the target resequencing analysis of a
predeﬁned panel of commonly implicated 8 sarcomere protein
genes should be performed using next-generation sequencing. If
no causative mutation is found in sarcomere genes, participation
in the WES research project (shown above) is recommended for
clarifying the full repertoire of HCM-causing mutations. These
causative mutations have to be recorded in combination with
the clinical phenotype. We are just taking the ﬁrst step toward
clinical sequencing for HCM patients. In order to achieve routine
clinical sequencing in everyday cardiology practice, further large
efforts are needed.References
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